Haemonetics Corporation (NYSE:HAE) is looking for M&A. During the company?s second quarter of 2024 earnings call, James C. D'Arecca, Chief Financial Officer, Executive Vice President & Financial Officer said that ?At the end of our second quarter, we had $351 million of cash on hand, up $67 million since the beginning of this fiscal year. We also had $420 million of untapped revolving credit facility, providing additional liquidity to fund growth initiatives. We plan to utilize the majority of our U.S. cash balance potentially coupled with a small drawdown on the revolver to fund the acquisition of OpSens and expect our leverage ratio to be around 2.1x adjusted EBITDA after the close, allowing us to remain opportunistic with additional M&A and organic investments, both in the short term and in the long run?.

?And lastly, we remain committed to value creation for all our stakeholders. As our capital capacity continues to grow, we plan to put it to good use throughout our long-range plan to accelerate top and bottom line growth through additional M&A, organic growth investments and opportunistic share buybacks?.